Early Pharmacological Treatment of Acute Spasticity After Spinal Cord Injury
A legfontosabb adatok
- Ki végzi
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 4. fázis
- Résztvevők
- 55 fő, tervezett
- Kezdés
- 2024. dec.
- Várható befejezés
- 2029. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Early baclofen Intervention
- Usual routine care
- A regiszteradat frissítve
- 2024. augusztus 21.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a recent spinal cord injury from blunt trauma (not a stab or gunshot wound). It tests whether starting oral baclofen early, at the first signs of muscle stiffness (spasticity), helps recovery.
- Életkor
- 18 years or older
- Nem
- Male or female
- A betegség stádiuma
- Blunt (non-penetrating) traumatic spinal cord injury, AIS grade A to D, with the injury level (NLI) between C0 and L1.
A részvétel fő kizáró okai
- Spinal cord damage not caused by injury, or a penetrating injury such as a stab or gunshot wound
- AIS grade E on admission, cauda equina syndrome, or injury level below L1
- Moderate or severe brain injury, or an earlier nerve disease such as stroke, Parkinson's disease or multiple sclerosis
- People who cannot take oral baclofen, or who have kidney failure (renal insufficiency)
- Major memory or thinking problems that prevent consent or tests, or being unlikely to come to visits
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female aged 18 years or older
- Blunt (non-penetrating) traumatic SCI
- AIS grade A to D
- NLI between C0 and L1
- Patient willing and able to provide informed consent
Ki nem vehet részt
- Non-traumatic SCI (e.g. tumor, infection, transverse myelitis, etc.)
- Cauda equina syndrome or NLI below L1
- Pre-existing neurological disorders (cerebrovascular disease, Parkinson's disease, multiple sclerosis, etc.)
- Renal insufficiency
- Contraindication to oral baclofen use (needs clearance from attending physician and pharmacological consultant)
- AIS grade E upon admission
- Penetrating tSCI (from stab wound, gunshot injury, etc.)
- Moderate or severe brain injury (mild traumatic brain injury not an exclusion criteria)
- Major cognitive deficits precluding informed consent and/or assessments
- Unlikely to comply with scheduled visits (e.g. living in another country)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of this clinical trial is to evaluate if early detection of spasticity and immediate treatment with oral baclofen during acute care prevents problematic spasticity and improves neurofunctional recovery after tSCI.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are :
1. Assess the safety of early baclofen treatment during acute care after SCI. 2. Compare the neurofunctional outcomes between the early baclofen group and the control group up to 6 months after tSCI, in terms of mobility, global functional independence, neurological recovery, pain and spasticity.
The early baclofen group will receive oral administration of baclofen as soon as any sign of acute spasticity is observed. The dose is started initially at 5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic. The control group however will receive the "usual routine care" at our institution as per which baclofen is initiated by the attending physician (i.e. physiatrist or spine surgeon) only when acute spasticity becomes severe and problematic.
A vizsgálat 2 csoportja
- Early Baclofen treatment groupA vizsgált kezelés
Oral baclofen will be started as soon as any sign of acute spasticity consisting of spasms, velocity-dependent hypertonia and/or clonus is observed. Oral baclofen will be initiated the same day as when signs of spasticity are first observed. Dosage : oral administration of baclofen is started initially at 5 mg three times a day. The dose is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response,
Kezelés: Early baclofen Intervention
- Control groupEgyéb csoport
The control group will receive the "usual routine care" as per which baclofen is prescribed only when acute spasticity becomes severe and problematic. In the presence of problematic spasticity, oral administration of baclofen is started initially at 5 mg three times a day. The dose is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response.
Kezelés: Usual routine care
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Early Pharmacological Treatment of Acute Spasticity After Spinal Cord Injury to Promote Long-term Neurofunctional Recovery: a Randomized Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2024. augusztus 21.